Co-amoxiclav

ApprovedSmall molecule

IImperial College London

Co-amoxiclav is one of 73 small molecule programs targeting Bacterial Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial PneumoniaActive, not recruiting

AmputationActive, not recruiting

Bacterial PneumoniaApproved

Active, not recruiting

AmputationApproved

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Bacterial Pneumonia

#DrugCompanyPhaseTrials

Teflaro

AbbVie

Approved

3 2

Biaxin

AbbVie

Approved

1 3

Ketek

Levaquin

2 5

Avelox

Bayer

Phase 3

5 6

Zyvox

Pfizer

Phase 3

4 7

Tygacil

PPrism Pharmaceuticals

Amikin

Avycaz

PPhiladelphia Eye Associates

Primaxin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Wound Infection2 trials

Prophylaxis Of Wound Infections- Antibiotics in Renal Donation

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT02089568·284 enrolled

Does Antibiotics Use During Surgery Help to Decrease Wound Infection and Increase Success After Ear Surgery in Children

Completed·TTribhuvan University, Nepal·Phase 4·NCT03700814·60 enrolled

Bacterial Pneumonia1 trial

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

Recruiting·—·Phase 4·NCT06804096·160 enrolled

Amputation1 trial

The Amputation Surgical Site Infection Trial (ASSIT)

Completed·HHull University Teaching Hospitals NHS Trust·Phase 4·NCT02018094·160 enrolled

Antibiotic1 trial

Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite

Terminated·JJawaharlal Institute of Postgraduate Medical Education & Research·Phase 4·NCT02570347·66 enrolled

Antibiotic Prophylaxis1 trial

Antibiotic Prophylaxis for PEG in Children

Unknown status·AAzienda Policlinico Umberto I·Phase 4·NCT01870167·90 enrolled

2 more indications

Complication1 trial

Preoperative Dose of Co-amoxiclav for Prevention of Postoperative Complications in Dentoalveolar Surgery

Unknown status·TTaibah University·N/A·NCT03844776·135 enrolled

Inflammation1 trial

Preschool Wheeze: Inflammation/Infection Guided Management

Completed·IImperial College London·Phase 2·NCT02517099·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Co-amoxiclav. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Co-amoxiclav compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Co-amoxiclav. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imperial College London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IImperial College London

Co-amoxiclav

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Wound Infection2 trials

Bacterial Pneumonia1 trial

Amputation1 trial

Antibiotic1 trial

Antibiotic Prophylaxis1 trial

Complication1 trial

Inflammation1 trial

References

Drug Info

Quick Facts

Related News